Hayley Stratton

Dr. Hayley Stratton

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2025 in Acta Tropica
Verified
Journal Article
Open access
LPLaura Prideaux
Laura Prideaux
MSMegan Sandeman
Megan Sandeman
HSHayley Stratton
Hayley Stratton
AKAnthony D Kelleher
Anthony D Kelleher
SSSimon Smith
Simon Smith
JHJosh Hanson
Josh Hanson
Despite the well-established link between diabetes mellitus and melioidosis, the precise impact of diabetes, its complications, and its therapy on the presentation and clinical course of melioidosis is incompletely defined. The influence of glycaemic control on the diverse clinical manifestations and the clinical course of melioidosis in patients with diabetes has also not been examined in detail. We examined all cases of culture-confirmed melioidosis in Far North Queensland, Australia between October 1, 2016, and April 30, 2024. We hoped to define the impact of diabetes, its control and its therapy on the patients' presentation and their clinical course. There were 321 cases of culture-confirmed melioidosis during the study period; the patients' median (interquartile range (IQR)) age was 57 (46-69) years, 212/321 (66 %) were male, 130/321 (41 %) identified as First Nations Australians. Diabetes was the most common risk factor for melioidosis in the cohort (163/321, 51 %); in 19/163 (12 %) this was a new diagnosis. The median (IQR)) glycosylated haemoglobin prior to presentation was 9.1 % (7.2-11.5) and 96/162 (59 %) with complete data had established macrovascular or microvascular complications. People with diabetes were more likely - than people without diabetes - to have involvement of the liver (odds ratio (OR) 95 % confidence interval (CI): 9.68 (2.21-42.46), p = 0.003), the spleen (OR (95 % CI): 7.32 (1.64-32.80), p = 0.009) or to have disseminated disease (OR (95 % CI): 2.93 (1.26-6.78), p = 0.01). However, people with diabetes were no more likely than people without diabetes to require intensive care unit admission (OR (95 % CI): 0.82 (0.47-1.42), p = 0.48) or to die before hospital discharge (12/163 (7 %) versus 19/158 (12 %), OR (95 % CI): 0.58 (0.27-1.24), p = 0.16). Only 58/163 (36 %) with diabetes had specialist endocrinology review during their hospitalisation and only 22/72 (31 %) with accessible data had good glycaemic control (glycosylated haemoglobin ≤7 %) in the 12 months after discharge, increasing their risk of subsequent diabetic complications. Of the 151 people with diabetes surviving their hospitalisation, 26 (17 %) died, at a median (IQR) of 1.0 (0.40-4.1) years after discharge. Of the individuals with diabetes who had completed five years of follow up, 21/60 (35 %) had died at a median (IQR) age of 67 (51-84) years. Individuals with diabetes and melioidosis are more likely to have liver and spleen abscesses and disseminated disease than individuals without diabetes, manifestations that appear to be linked directly to glycaemic control. In Australia's well-resourced health system <10 % of patients with diabetes and melioidosis will die from their infection. However, five-year all-cause mortality in individuals with diabetes who survive their melioidosis is greater than 30 %, emphasising the importance of close, holistic multidisciplinary follow-up to ensure their optimal long-term health outcomes.

25 May 2026 in Acta Tropica
Verified
Journal Article
Open access
SHSamuel Hart
Samuel Hart
SSSimon Smith
Simon Smith
BNBen Nash
Ben Nash
HSHayley Stratton
Hayley Stratton
PRPatrick Rosengren
Patrick Rosengren
JHJosh Hanson
Josh Hanson
The case-fatality rate of patients with leptospirosis requiring intensive care unit (ICU) admission in resource-limited settings can exceed 50%. However, the optimal care of critically ill patients with this life-threatening infection is incompletely defined. This retrospective study examined the demographic, clinical, laboratory and imaging findings in consecutive individuals with a laboratory-confirmed diagnosis of leptospirosis admitted to the ICU of an Australian referral hospital between May 2015 and April 2025. The care provided to the patients was correlated with their clinical course. The median (interquartile range, IQR) of the 60 individuals was 43 (26-65) years; 49/60 (82%) had no pre-existing comorbidity. The patients' median (IQR) APACHE-III score was 63 (46-89). Multi-organ dysfunction was common: 48/60 (80%) needed vasopressor support, a lung protective ventilation strategy was employed in the 16/60 (27%) requiring mechanical ventilation and renal replacement therapy was initiated in 12/60 (20%) using standard indications. Two patients received extracorporeal membrane oxygenation. While awaiting a diagnosis of leptospirosis, patients were managed using contemporary principles of sepsis care: all 60 patients received antibiotics, fluid resuscitation was conservative and transfusion of blood products was restrictive. Corticosteroids were provided to 23/60 (38%), but this was usually short course hydrocortisone therapy for blood pressure support. All 60 patients survived to discharge and were alive 90 days later. Leptospirosis can cause life-threatening multi-organ failure in young people without comorbidity. However, in Australia's well-resourced health system, excellent outcomes can be achieved using standard principles of sepsis management before the diagnosis is confirmed.

3 July 2019 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
PDF file
HSHayley Stratton
Hayley Stratton
AAAleisha J Anderson
Aleisha J Anderson
MOMatthew P O'Brien
Matthew P O'Brien
NPNeil Powers
Neil Powers
MRMadhur Ravikumara
Madhur Ravikumara
BHBriony Hazelton
Briony Hazelton

10 May 2022 in Internal Medicine Journal
Verified
Journal Article
Closed access
HSHayley Stratton
Hayley Stratton
PBPaul Buntine
Paul Buntine
RNReginald Bo Ren Ng
Reginald Bo Ren Ng
JFJoy Jiayu Fu
Joy Jiayu Fu
NJNeetima Joshi
Neetima Joshi
JLJillian S. Y. Lau
Jillian S. Y. Lau

2 November 2026 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PRPatrick Rosengren
Patrick Rosengren
SSSimon Smith
Simon Smith
LJLiam Johnston
Liam Johnston
TCThomas Coombs
Thomas Coombs
NCNicholas Cairns
Nicholas Cairns
JHJosh Hanson
Josh Hanson
Objectives: In some resource‐limited settings the case‐fatality rate of severe leptospirosis can exceed 50%. Early recognition of severe disease can expedite transfer to referral centres for advanced supportive care. The entirely clinical, 3‐point SPiRO score can be calculated rapidly at presentation to predict a patient's subsequent clinical course. In its derivation study, a SPiRO score of 0 had a negative predictive value (NPV) for intensive care unit (ICU) admission of 98% (95% confidence interval [CI]: 96–99). In this validation cohort we sought to confirm the SPiRO score's prognostic utility and to compare its performance to other leptospirosis‐specific and general disease severity scores. Methods: We examined consecutive adults presenting to four high‐caseload hospitals in tropical Australia with laboratory‐confirmed leptospirosis between June 2016 and April 2026. The SPiRO score's ability to predict ICU admission before hospital discharge was compared with that of the leptospirosis‐specific QuickLepto score and commonly used disease severity scores, namely the SOFA, qSOFA, qSOFA‐lactate, NEWS‐2, qNEWS, UVA and the SIRS scores. Results: There were no deaths in 309 episodes of leptospirosis, but in 62 (20%) there was an ICU admission. The SPiRO score performed as well as, or better than, all the other scores in predicting ICU admission. The area under the receiver operating characteristic curve for the SPiRO score was 0.83 (95% CI: 0.77–0.89); only the SOFA score had a higher value: 0.84 (0.79–0.90), although the difference was not statistically significant ( p = 0.08). The SPiRO score had the highest NPV for ICU admission of any of the scores: 95 (95% CI: 91–97)%. Conclusions: The SPiRO score can be calculated easily at the bedside at presentation to expedite the recognition of patients with leptospirosis who are most likely to deteriorate. In resource‐limited settings this entirely clinical score can also help reduce unnecessary escalation of care, optimising the use of finite health resources.